Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Taiko Pharmaceutical Co., Ltd. (4574:JPX), powered by AI.
Taiko Pharmaceutical Co., Ltd. is currently trading at ¥260. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Taiko Pharmaceutical Co., Ltd. on Alpha Lenz.
Taiko Pharmaceutical Co., Ltd.'s P/E ratio is 14.2.
“Taiko Pharmaceutical Co., Ltd. trades at a P/E of 14.2 (undervalued) with solid ROE of 11.2%.”
Ask for details →Taiko Pharmaceutical Co., Ltd. is a distinguished company within the pharmaceutical industry, committed to the research, development, manufacturing, and marketing of pharmaceutical products. This company primarily focuses on the development of drugs that tackle infectious diseases and respiratory conditions, significantly contributing to the healthcare sector. Its product portfolio often includes antiseptics, decongestants, and various hygienic solutions that are crucial in both hospital and consumer settings. With an emphasis on innovation, Taiko Pharmaceutical continually invests in new medical technologies and product improvements to meet evolving healthcare demands. As a player in the pharmaceutical market, the company underscores its role by addressing public health needs and enhancing the quality of life through its medicinal products. Its market significance is evident in the way it supports healthcare providers and consumers in maintaining health standards and combating diseases, thereby influencing the broader pharmaceutical landscape.
“Taiko Pharmaceutical Co., Ltd. trades at a P/E of 14.2 (undervalued) with solid ROE of 11.2%.”
Ask for details →Taiko Pharmaceutical Co., Ltd. (ticker: 4574) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 214 employees. Market cap is $13.1B.
The current price is 260 with a P/E ratio of 14.15x and P/B of 1.53x.
ROE is 11.20% and operating margin is 7.18%. Annual revenue is $6.4B.